In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB Bets on Focus, Not Diversification

Executive Summary

In contrast to some Big Pharmas, mid-sized UCB has shifted from a diversified to a very focused business model. That means it's relying heavily on commercial success for its three newest drugs. If the new products take off, UCB could by 2012 be delivering stronger earnings growth than its more diversified peers, just as some of them begin to face the worst of their patent cliffs. But it has little room to maneuver if even one of these disappoints.

You may also be interested in...



UCB Provides Synosia With Its First Out-Licensing Deal And Leads Its $30M Series C Funding

UCB gains rights to Synosia's potential Parkinson's disease therapies in deal that could be worth $725 million in milestones

AZ Continues To Buy Pipeline With $100M Rigel Deal

Facing a raft of patent expiries, AstraZeneca pays richly for Rigel's Phase II oral RA candidate.

Cephalon Buys Swiss Generics Firm Mepha, Talking Up Diversification

Company will buy Mepha for roughly $590 million in cash to double the size of its international business and diversify its business mix.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel